Celsion Co.

Imunon reported in the Q1‑2026 earnings call rising R&D spending due to the OVATION‑3 study of IMNN‑001, while general administrative costs were kept stable. OVATION‑2 data show an overall survival benefit of 14.7 months for IMNN‑001. Management plans to enroll the last patient for OVATION‑3 by Q1‑2029 and is seeking strategic partnerships to finance the program; the premarket share price rose 4.03% as a result. » Más en de.investing.com

IMUNON presented data from the phase‑2 OVATION 2 trial showing that the combination of IMNN‑001 with standard chemotherapy improved median overall survival by 13 months versus chemotherapy alone. The company announced site activations and recruitment for the regulatory phase‑3 trial OVATION 3, exceeding expectations. IMNN‑001 is a DNA‑based immunotherapy (interleukin‑12 plasmid) with a favorable safety profile; IMUNON has more cash than debt but is not expected to be profitable this year. » Más en de.investing.com